Access this webinar to hear from Greg Medlock from Vedanta Biosciences about how he is using automation to power discovery of microbiome therapeutics.
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s pipeline includes clinical-stage product candidates being evaluated for the prevention of recurrent C. difficile infection and inflammatory bowel diseases and a preclinical candidate for the prevention of Gram-negative infections. Each product candidate is a defined consortia of bacteria that have been lyophilized and filled in enteric coated capsules.
Greg Medlock, PhD
Director of Research and Head of Analytical Development and Early-Stage Process Development, Vedanta Biosciences
His work at Vedanta Biosciences is focused on understanding and predicting interactions between bacterial strains and developing new manufacturing processes and characterization approaches for defined bacterial consortia as drugs. Prior to this role, he was an Assistant Professor in the Department of Pediatrics at the University of Virginia, where his laboratory developed new experimental and computational methods for predicting interactions between bacterial strains. He completed post-doctoral training in Pediatric Gastroenterology at the University of Virginia, earned his PhD in Biomedical Engineering at the University of Virginia, and earned his undergraduate degree in Bioengineering at the University of Washington.